Remission of chronic type ATL in a patient with rheumatoid arthritis after withdrawing methotrexate and infliximab combination therapy: a case report

References

• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740–1751.
   PubMed Web of Science ®Google Scholar
• Kameda T, Dobashi H, Miyatake N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2014;66:1302–1309.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Nakamine H, et al. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci. 2010;101:1309–1313.
   PubMed Web of Science ®Google Scholar
• Kojima M, Itoh H, Hirabayashi K, et al. Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract. 2006;202:679–685.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322–331.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein–Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–28.
   PubMed Web of Science ®Google Scholar
• Berti A, Felicetti M, Peccatori S, et al. EBV-induced lymphoproliferative disorders in rheumatic patients: a systematic review of the literature. Joint Bone Spine. 2017 [cited Feb 11]. DOI:10.1016/j.jbspin.2017.01.006
   Web of Science ®Google Scholar
• Inui Y, Matsuoka H, Yakushijin K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015;56:3045–3051.
   PubMed Web of Science ®Google Scholar
• Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol. 2017;31:1–8.
   Google Scholar
• Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R45.
   PubMed Web of Science ®Google Scholar
• Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene. 2003;22:5131–5140.
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20:5217–5225.
   PubMed Web of Science ®Google Scholar
• Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol. 2012;84:327–335.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein–Barr virus infection. Am J Hematol. 2007;82:1106–1109.
   PubMed Web of Science ®Google Scholar
• Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014;41:293–299.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42:564–571.
   PubMed Web of Science ®Google Scholar
• Yamada T, Nakajima A, Inoue E, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int. 2011;31:1487–1492.
   PubMed Web of Science ®Google Scholar
• Harigai M, Nanki T, Koike R, et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying anti rheumatic drugs compared to the general population: a nationwide cohort study in Japan. Mod Rheumatol. 2016;26:642–650.
   PubMed Web of Science ®Google Scholar
• Kawano N, Shimoda K, Ishikawa F, et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation. 2006;82:840–843.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Ueki Y, Saito S, et al. Development of adult T-cell leukemia in a patient with rheumatoid arthritis treated with tocilizumab. Intern Med. 2013;52:1983–1986.
   PubMed Web of Science ®Google Scholar
• Bittencourt AL, Oliveira PD, Bittencourt VG, et al. Adult T-cell leukemia/lymphoma triggered by adalimumab. J Clin Virol. 2013;58:494–496.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Suzumiya J, Sato K, et al. Survival of patients with HTLV-I-associated lymph node lesions. J Pathol. 1999;189:539–545.
   Web of Science ®Google Scholar
• Tokuhira M, Saito S, Okuyama A, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2017 [cited Sep 7]. DOI:10.1080/10428194.2017.1369073
   Web of Science ®Google Scholar
• Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211–1219.
   PubMed Web of Science ®Google Scholar
• Okayama A, Stuver S, Matsuoka M, et al. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer. 2004;110:621–625.
   PubMed Web of Science ®Google Scholar
• Umekita K, Umeki K, Miyauchi S, et al. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series. Mod Rheumatol. 2015;25:794–797.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56:155–167.
   PubMed Web of Science ®Google Scholar
• Saito S, Kaneko Y, Yamaoka K, et al. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford). 2017;56:940–946.
   PubMed Web of Science ®Google Scholar